Citations 1
The role of imaging studies in predicting time to first treatment and overall survival in high‐count monoclonal B‐cell lymphocytosis
Kosydar, Samuel , Archibald, William J. , Hampel, Paul J. , Call, Timothy G. , Achenbach, Sara J., Rabe, Kari G. , Hanson, Curtis A. , Koehler, Amber B. , Muchtar, Eli , Kenderian, Saad S. , Leis, José F., Schwager, Susan M., Wang, Yucai , Hilal, Talal , Parrondo, Ricardo D , Shi, Min , Parikh, Sameer A , Chaffee, Kari G. , Kenderian, Saad Sirop , Muchtar, E , Kosydar, Samuel R , Achenbach, Sara J., Wang, Yucai , Roeker, Lindsey E. , Hilal, Talal , Tsang, Mazie , Braggio, Esteban , Slager, Susan L. , Kay, Neil E. , Parikh, Sameer A.
British Journal of Haematology | July 16, 2025 | Volume: 207 | Issue: 3 | Pages: 860-868
SummaryIn individuals with high‐count monoclonal B‐cell lymphocytosis (MBL), we investigated if lymphadenopathy or splenomegaly found by imaging was associated with shorter time to first chronic lymphocytic leukaemia (CLL) therapy (TTFT) and overall survival (OS). Individuals with MBL seen at Mayo Clinic (2002–2019) were retrospectively divided into three cohorts based on imaging studies within 1 year of diagnosis: no imaging studies (Cohort A); imaging with no evidence of lymphadenopathy/splenomegaly (Cohort B); imaging with evidence of lymphadenopathy/splenomegaly (Cohort C). We compared baseline characteristics, TTFT and OS across the MBL cohorts to a cohort of individuals with small lymphocytic lymphoma (SLL). A total of 1078 patients were included: 640 with MBL and 438 with SLL. Compared to Cohort B, individuals in Cohort C were more likely to have unmutated immunoglobulin heavy chain variable region (IGHV) (43% vs. 25% p = 0.016), high‐risk fluorescence in situ hybridization (FISH) (del17p and del11q in 15% vs. 4%, p = 0.038) and higher expression of CD38 (31% vs. 16%; p = 0.011). After adjusting for sex and CLL‐International Prognostic Index (IPI), lymphadenopathy/splenomegaly was associated with a shorter TTFT (hazard ratio [HR] = 2.04, 95% confidence interval [CI]: 1.02–4.04, p = 0.042) but not OS (HR = 1.09, 95% CI: 0.62–1.92, p = 0.775). Lymphadenopathy/splenomegaly on imaging in individuals with high‐count MBL is associated with a more unfavourable risk profile and shorter time to first CLL‐directed therapy.